Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$1.54 USD
+0.08 (5.48%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $1.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Century Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 173 | 316 | 223 | 76 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 4 | 4 | 5 | 3 | NA |
Total Current Assets | 177 | 320 | 228 | 79 | NA |
Net Property & Equipment | 72 | 83 | 58 | 15 | NA |
Investments & Advances | 90 | 53 | 137 | 2 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 2 | 2 | 2 | 1 | NA |
Total Assets | 361 | 487 | 437 | 107 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 3 | 5 | 8 | 8 | NA |
Current Portion Long-Term Debt | 1 | 7 | 2 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 10 | 10 | 6 | 4 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 4 | 7 | 0 | 0 | NA |
Total Current Liabilities | 18 | 30 | 16 | 12 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 111 | 111 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 4 | 11 | 10 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 176 | 184 | 41 | 33 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 180 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 840 | 824 | 785 | 218 | NA |
Retained Earnings | -656 | -519 | -388 | -292 | NA |
Other Equity | 0 | -2 | -1 | -32 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 185 | 303 | 396 | 73 | NA |
Total Liabilities & Shareholder's Equity | 361 | 487 | 437 | 107 | NA |
Total Common Equity | 185 | 303 | 396 | -106 | 0 |
Shares Outstanding | 60.30 | 58.90 | 54.60 | NA | NA |
Book Value Per Share | 3.06 | 5.14 | 7.26 | 0.00 | 0.00 |
Fiscal Year End for Century Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 196 | 192 | 173 | 170 | 156 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 8 | 4 | 4 | 5 |
Total Current Assets | 203 | 200 | 177 | 174 | 161 |
Net Property & Equipment | 69 | 69 | 72 | 82 | 84 |
Investments & Advances | 74 | 58 | 90 | 115 | 145 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 38 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 2 | 2 | 2 | 2 |
Total Assets | 416 | 349 | 361 | 398 | 417 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 3 | 6 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 1 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 8 | 10 | 10 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 5 | 4 | 4 | 7 |
Total Current Liabilities | 19 | 16 | 18 | 20 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 113 | 110 | 111 | 112 | 109 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 194 | 171 | 176 | 178 | 170 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 937 | 862 | 840 | 837 | 832 |
Retained Earnings | -715 | -684 | -656 | -616 | -584 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 222 | 178 | 185 | 219 | 248 |
Total Liabilities & Shareholder's Equity | 416 | 349 | 361 | 398 | 417 |
Total Common Equity | 222 | 178 | 185 | 219 | 248 |
Shares Outstanding | 84.50 | 64.80 | 60.30 | 59.70 | 59.50 |
Book Value Per Share | 2.63 | 2.75 | 3.06 | 3.67 | 4.16 |